Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
ORMP's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: No Debt )
ORMP' s 10-Year Cash to Debt Range
Min: 1.06   Max: No Debt
Current: No Debt

F-Score: 2
Z-Score: 92.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -52.05
ORMP's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: -52.05 )
ORMP' s 10-Year ROE (%) Range
Min: -630.8   Max: -41.92
Current: -52.05

-630.8
-41.92
ROA (%) -48.87
ORMP's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: -48.87 )
ORMP' s 10-Year ROA (%) Range
Min: -4600   Max: -36.08
Current: -48.87

-4600
-36.08
ROC (Joel Greenblatt) (%) -71733.33
ORMP's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: -71733.33 )
ORMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -156600   Max: 124.11
Current: -71733.33

-156600
124.11
EBITDA Growth (%) -2.20
ORMP's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: -2.20 )
ORMP' s 10-Year EBITDA Growth (%) Range
Min: -10.8   Max: 57
Current: -2.2

-10.8
57
EPS Growth (%) -1.60
ORMP's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: -1.60 )
ORMP' s 10-Year EPS Growth (%) Range
Min: -24.7   Max: 183
Current: -1.6

-24.7
183
» ORMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ORMP



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.70
ORMP's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: 3.70 )
ORMP' s 10-Year P/B Range
Min: 0   Max: 28.2
Current: 3.7

0
28.2
EV-to-EBIT -16.11
ORMP's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: -16.11 )
ORMP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -16.11

Current Ratio 32.26
ORMP's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: 32.26 )
ORMP' s 10-Year Current Ratio Range
Min: 0.13   Max: 67.68
Current: 32.26

0.13
67.68
Quick Ratio 32.26
ORMP's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: 32.26 )
ORMP' s 10-Year Quick Ratio Range
Min: 0.13   Max: 67.68
Current: 32.26

0.13
67.68

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.40
ORMP's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: 5.40 )
ORMP' s 10-Year Price/Net Cash Range
Min: 4.43   Max: 139.2
Current: 5.4

4.43
139.2
Price/Net Current Asset Value 5.30
ORMP's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: 5.30 )
ORMP' s 10-Year Price/Net Current Asset Value Range
Min: 4.38   Max: 139.2
Current: 5.3

4.38
139.2
Price/Tangible Book 3.70
ORMP's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: 3.70 )
ORMP' s 10-Year Price/Tangible Book Range
Min: 3.77   Max: 75.6
Current: 3.7

3.77
75.6
Earnings Yield (Greenblatt) 8.30
ORMP's Earnings Yield (Greenblatt) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: 8.30 )
ORMP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 9.3
Current: 8.3

0
9.3
Forward Rate of Return (Yacktman) -5.76
ORMP's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ORMP: -5.76 )
ORMP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -5.76

Business Description

Industry: »
Compare: » details
Traded in other countries:OJU1.Germany
Oramed Pharmaceuticals Inc. was incorporated on April 12, 2002, under the laws of the State of Nevada. It is a pharmaceutical Company engaged in the research and development of innovative pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, rectal application of insulin, use of oral ingestible capsules or tablets for delivery other polypeptides and use of rectal application for delivery of other polypeptides. The Company is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD0801) currently in Phase 2 clinical trials. The Company plans to continue to conduct clinical trials to show the effectiveness of its technology. It filed two additional provisional patents for a suppository application to its technology portfolio. The first patent focuses on a rectal application for insulin. The second patent focuses on the usage of this rectal application to other polypeptides that at present are only available in injection. On September 16, 2008 it announced the launch of pre-clinical trials of ORMD 0901, a GLP1-analog. Its research pipeline includes other product candidates, such as an Oral GLP-1. Competitors include pharmaceutical, medical products, chemical and specialized biotechnology companies, many of which have financial, technical and marketing resources. It is subject to Federal and state laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with research are applicable to its activities.
» More Articles for NAS:ORMP

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
ORAMED PHARMACEUTICALS INC. Financials Jul 19 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report Jul 14 2014
Oramed Pharmaceuticals to Present at the BIO International Convention in San Diego Jun 23 2014
Oramed Pharmaceuticals to Present at the American Diabetes Association 74th Scientific Sessions on... Jun 10 2014
The Importance Of Being Oral Jun 03 2014
Oramed Pharmaceuticals Added to the Morgan Stanley Capital International (MSCI) MicroCap Index May 29 2014
Barclays to hold a conference May 29 2014
Oramed to Present at Jefferies Global Healthcare Conference on June 2 in New York City May 27 2014
Does Oramed Pharmaceuticals Pass The Smell Test? May 23 2014
Oramed Pharmaceuticals to Present at the IATI Israel Innovation Conference in Tel Aviv May 19 2014
Oramed to Present Poster on its Oral Insulin Capsule at the Yale Diabetes Symposium May 13 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial... Apr 24 2014
Oramed Pharmaceuticals Presents Data from Phase IIa Trial with ORMD-0801 in Type 2 Diabetes at the... Apr 24 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report Apr 10 2014
Oramed Granted Patent in Hong Kong for Oral Administration of Insulin Apr 10 2014
Oramed Can Benefit As MannKind Opens The Diabetes Market For Novel Drugs Apr 08 2014
Oramed Pharmaceuticals Announces First Patient Enrolled in a US Phase 2a Trial for ORMD-0801 in... Mar 27 2014
LifeSci Advisors Initiates Coverage of Oramed Pharmaceuticals Mar 20 2014
Oramed Granted its 3rd Patent in Australia for Oral Administration of Exenatide Mar 11 2014
Oramed granted 3rd patient in Australia for oral administration of exenatide Mar 11 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide